BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests

被引:69
作者
Hida, Tomoyuki [1 ,3 ,4 ]
Hamasaki, Makoto [1 ]
Matsumoto, Shinji [1 ]
Sato, Ayuko [6 ]
Tsujimura, Tohru [6 ]
Kawahara, Kunimitsu [7 ]
Iwasaki, Akinori [2 ]
Okamoto, Tatsuro [5 ]
Oda, Yoshinao [3 ]
Honda, Hiroshi [4 ]
Nabeshima, Kazuki [1 ]
机构
[1] Fukuoka Univ Hosp, Dept Pathol, Fukuoka, Japan
[2] Fukuoka Univ Hosp, Dept Thorac Surg, Fukuoka, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[6] Hyogo Coll Med, Dept Pathol, Nishinomiya, Hyogo, Japan
[7] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Pathol, Osaka, Japan
关键词
BAP1; Fluorescence in situ hybridization; Immunohistochemistry; Malignant pleural mesothelioma; p16; ROC analysis; BRCA1-ASSOCIATED PROTEIN-1; DELETION; GLUT-1; CDKN2A; IMP3; HYBRIDIZATION; DISCRIMINATE; GUIDELINES; MUTATIONS; MELANOMA;
D O I
10.1111/pin.12453
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Differentiation of malignant pleural mesothelioma (MPM) from benign mesothelial proliferation remains problematic. Loss of nuclear staining of BRCA1-associated protein 1 (BAP1; detected using immunohistochemistry (IHC)) and homozygous deletion (HD) of p16 (detected using fluorescence in situ hybridization (FISH)) are useful for differentiation of MPM from reactive mesothelial hyperplasia (RMH), but the correlation between BAP1 expression loss and p16 HD has not been fully described. We performed BAP1 IHC and p16-specific FISH for 40 MPM and 20 RMH cases, and measured proportions of cells showing BAP1 expression and p16 HD for each case. The diagnostic accuracy for MPM and the cut-off values of the two methods were assessed using receiver operating characteristic (ROC) analysis. BAP1 expression loss, p16 HD and coexistence of both were present in 27 (67.5 %), 27 (67.5 %) and 17 (42.5%) MPM cases, respectively. Three MPM cases (7.5 %) and all 20 RMH cases had neither BAP1 loss nor p16 HD. There was no correlation between the results of the two methods. Their combination showed higher sensitivity (92.5 %, 37/40) and estimated probability than BAP1 IHC and p16-specific FISH used alone. BAP1 IHC and p16-specific FISH have independent diagnostic value, and have increased reliability when used in combination, for MPM diagnosis.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 39 条
[1]   Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers [J].
Abdel-Rahman, Mohamed H. ;
Pilarski, Robert ;
Cebulla, Colleen M. ;
Massengill, James B. ;
Christopher, Benjamin N. ;
Boru, Getachew ;
Hovland, Peter ;
Davidorf, Frederick H. .
JOURNAL OF MEDICAL GENETICS, 2011, 48 (12) :856-859
[2]   Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology [J].
Andrici, Juliana ;
Sheen, Amy ;
Sioson, Loretta ;
Wardell, Kathryn ;
Clarkson, Adele ;
Watson, Nicole ;
Ahadi, Mahsa S. ;
Farzin, Mahtab ;
Toon, Christopher W. ;
Gill, Anthony J. .
MODERN PATHOLOGY, 2015, 28 (10) :1360-1368
[3]   The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2 [J].
Attanoos, RL ;
Griffin, A ;
Gibbs, AR .
HISTOPATHOLOGY, 2003, 43 (03) :231-238
[4]   Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma [J].
Bidlingmaier, Scott ;
He, Jiang ;
Wang, Yong ;
An, Feng ;
Feng, Jinjin ;
Barbone, Dario ;
Gao, Dongwei ;
Franc, Ben ;
Broaddus, V. Courtney ;
Liu, Bin .
CANCER RESEARCH, 2009, 69 (04) :1570-1577
[5]   Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma [J].
Bjorkqvist, AM ;
Tammilehto, L ;
Anttila, S ;
Mattson, K ;
Knuutila, S .
BRITISH JOURNAL OF CANCER, 1997, 75 (04) :523-527
[6]   The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma [J].
Bott, Matthew ;
Brevet, Marie ;
Taylor, Barry S. ;
Shimizu, Shigeki ;
Ito, Tatsuo ;
Wang, Lu ;
Creaney, Jenette ;
Lake, Richard A. ;
Zakowski, Maureen F. ;
Reva, Boris ;
Sander, Chris ;
Delsite, Robert ;
Powell, Simon ;
Zhou, Qin ;
Shen, Ronglai ;
Olshen, Adam ;
Rusch, Valerie ;
Ladanyi, Marc .
NATURE GENETICS, 2011, 43 (07) :668-U81
[7]   BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs [J].
Carbone, Michele ;
Ferris, Laura Korb ;
Baumann, Francine ;
Napolitano, Andrea ;
Lum, Christopher A. ;
Flores, Erin G. ;
Gaudino, Giovanni ;
Powers, Amy ;
Bryant-Greenwood, Peter ;
Krausz, Thomas ;
Hyjek, Elizabeth ;
Tate, Rachael ;
Friedberg, Joseph ;
Weigel, Tracey ;
Pass, Harvey I. ;
Yang, Haining .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[8]  
CHENG JQ, 1994, CANCER RES, V54, P5547
[9]   BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations [J].
Cigognetti, Marta ;
Lonardi, Silvia ;
Fisogni, Simona ;
Balzarini, Piera ;
Pellegrini, Vilma ;
Tironi, Andrea ;
Bercich, Luisa ;
Bugatti, Mattia ;
Rossi, Giulio ;
Murer, Bruno ;
Barbareschi, Mattia ;
Giuliani, Silvia ;
Cavazza, Alberto ;
Marchetti, Gianpietro ;
Vermi, William ;
Facchetti, Fabio .
MODERN PATHOLOGY, 2015, 28 (08) :1043-1057
[10]   Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England [J].
Damhuis, R. A. ;
Khakwani, A. ;
De Schutter, H. ;
Rich, A. L. ;
Burgers, J. A. ;
van Meerbeeck, J. P. .
LUNG CANCER, 2015, 89 (02) :212-217